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1. Introduction {#term2428-sec-0001}
===============

Unmet medical needs demand the further development of truly innovative new medical products and treatment options, including regenerative medicine products. Expedited‐approval pathways and programmes, priority review or programmes alternative to the standard review processes for medical products have been developed and legislation has been enacted for the rapid commercialization of innovative medical products and for improved access for patients in need (US Food and Drug Administration, [2014c](#term2428-bib-0020){ref-type="ref"}), (European Medicines Agency, [2016b](#term2428-bib-0007){ref-type="ref"}). Some of these alternative pathways and programmes reduce the evidentiary requirement in the pre‐marketing development of medical products, which typically require demonstration of safety, efficacy or provision of risk‐benefit confirmatory data before product commercialization in the standard review process, and rather, make these evidentiary requirements post‐marketing obligations, such as the submission of post‐marketing clinical study data to the appropriate authorities.

Since the late 1980s, multiple alternative pathways or programmes have been introduced in the United States of America (USA) and the European Union (EU), and in the past two decades, many medical products (drugs, biologics and medical devices) have thus been approved (United States Government Accountability Office, [2015c](#term2428-bib-0022){ref-type="ref"}; Boucaud‐Maitre and Altman, [2016](#term2428-bib-0002){ref-type="ref"}). In the last decade, regulatory issues associated with these expedited‐approval pathways or programmes have arisen and need to be addressed. In the USA, an increasingly large number of minimally innovative or clinically transformative therapeutics are benefitting from the expedited development and review programmes created by the US Food and Drug Administration (FDA) (Kesselheim *et al.*, [2015](#term2428-bib-0009){ref-type="ref"}). A large number of obligations to collect and report post‐marketing data on approved drugs have been bypassed by sponsors (Moore and Furberg, [2014](#term2428-bib-0016){ref-type="ref"}). In the EU also, there have been delays or discrepancies in fulfilling post‐marketing obligations in more than one third of granted conditional approvals (Banzi *et al.*, [2015](#term2428-bib-0001){ref-type="ref"}). Objections by the US congress or patient advocacy groups have reversed withdrawal decisions previously made by the legislative authorities (Dhruva and Redberg, [2010](#term2428-bib-0004){ref-type="ref"}).

Recently, the Japanese government reformed its pharmaceutical affairs legislation, which regulates all pharmaceutical products and medical devices, and created a new regulation called the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act) in November 2014 (Hara*, et al.*, [2014](#term2428-bib-0008){ref-type="ref"}). Under this new Act, regenerative medicine products are classified independently from conventional pharmaceuticals and medical devices and are defined as processed human cells that are intended to be used 1) for either (a) the reconstruction, repair or formation of structures or functions of the human body or (b) the treatment or prevention of human diseases, or 2) for gene therapy.

This new Act also introduces conditional and time‐limited approval for regenerative medicine products, and one product has already been granted conditional and time‐limited authorization based on the probable benefit that was demonstrated by pilot clinical trial data. Critics claim that this new system would enable the approval of medical products with unconfirmed efficacy (Nature Editorials, [2015](#term2428-bib-0005){ref-type="ref"}; Sipp, [2015](#term2428-bib-0019){ref-type="ref"}). Because the first approved medical product is covered by Japanese national health insurance, critics also claim that insurance organizations and patients will be taking on some of the risk and financial burden of phase III studies that should instead be shouldered by the sponsor to confirm product safety and efficacy (McCabe and Sipp, [2016](#term2428-bib-0010){ref-type="ref"}). Aside from commentaries or letters, to our knowledge, there are no published studies that examine or analytically compare the legislative framework underlying each of these various regulations. In this study, we first compare the expedited‐approval systems in the USA and EU with the new approval pathway for regenerative medicine products in Japan, and then propose points for improvement of future systems.

2. Materials and methods {#term2428-sec-0002}
========================

2.1. Categorization of the US and EU expedited‐approval pathways or programmes and comparison with the new conditional and time‐limited approval of regenerative medicine products in Japan {#term2428-sec-0003}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Given the objective of the study, to compare the new expedited‐approval pathway in Japan with those existing in the USA and the EU, we selected 10 pathways and programmes in the USA and the EU that fulfill either of the following two conditions: 'Standard' approval is provided through an expedited review process;Exemption from demonstration of clinical effectiveness and conditional approval are granted.

All regulation documents pertaining to expedited approval of medical products were obtained from websites of the respective authorities: the FDA (US Food and Drug Admministration, [2016e](#term2428-bib-0021){ref-type="ref"}), the European Medicines Agency (EMA) (European Medicines Agency, [2016a](#term2428-bib-0006){ref-type="ref"}) and the Pharmaceuticals and Medical Devices Agency (PMDA) (Pharmaceuticals and Medical Devices Agency, [2016a](#term2428-bib-0017){ref-type="ref"}). Requirements related to collecting post‐marketing clinical data were also obtained through guidance documents or legislation. Information on the regulatory pathways and programmes in the USA and EU was categorized according to the following criteria: pre‐ and/or post‐marketing data requirements, evaluation of post‐marketing data, and existence of regulatory authority development support. Then, qualifying criteria (Table 3) of the USA and the EU pathways and programmes were identified and displayed to facilitate comparison with the new pathway in Japan.

2.2. Analysis of post‐marketing clinical data requirements for approved regenerative medicine products in Japan {#term2428-sec-0004}
---------------------------------------------------------------------------------------------------------------

In addition to regulation documents, the review report of two products, HeartSheet® (Ministry of Health, Labor and Welfare, [2015a](#term2428-bib-0011){ref-type="ref"}) and Temcell HS Injection® (Ministry of Health, Labor and Welfare, [2015b](#term2428-bib-0012){ref-type="ref"}), which have been approved under the new PMD Act as of the end of September 2016 (Pharmaceuticals and Medical Devices Agency, [2016b](#term2428-bib-0018){ref-type="ref"}) were obtained from the PMDA website. The clinical data submitted for obtaining marketing authorization and post‐marketing obligations were analysed.

3. Results {#term2428-sec-0005}
==========

3.1. Categorization of expedited‐approval pathways and programmes in the USA and EU {#term2428-sec-0006}
-----------------------------------------------------------------------------------

Table [1](#term2428-tbl-0001){ref-type="table-wrap"} summarizes the identified the pathways and programmes in the US and the EU for expedited approval or priority review of the medical products. Based on the criteria described in the Methods section, the pathways and programmes (Table [1](#term2428-tbl-0001){ref-type="table-wrap"}) were categorized into the following four groups (Table [2](#term2428-tbl-0002){ref-type="table-wrap"}): Expedited approval without post‐marketing obligations;Conditional approval with evaluation of required post‐marketing data after approval;Approval with limited patient cohort or indication with no confirmed efficacy data required for marketing approval and no post‐marketing obligations;Development support by the authority for expedited product approval.

###### 

Expedited‐approval pathways and programmes in the USA and EU

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Regulatory pathway (Authority, year of issue)**          **When to submit request and timeline for authority response**                                                                               **Qualifying criteria**\                                                                                                                                                                                                 **Features and mechanism of expedition**                                                                                                                **Post‐marketing data requirement**
                                                                                                                                                                                                          **(Scope and requirements)**                                                                                                                                                                                                                                                                                                                                                     
  ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **USA**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Priority review\                                           Submit with original BLA, NDA, or efficacy supplement\                                                                                       1\) A drug for a serious condition, AND with a significant improvement in safety or effectiveness, OR\                                                                                                                   Shorter review time of marketing application (6 months, compared with 10‐month standard review)                                                         Not requested
  (FDA, 1992)                                                Response within 60 calendar days of receipt of submission                                                                                    2) Supplement for a labeling change pursuant to a report on a pediatric study, OR\                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                          3) A drug designated as a qualified infection disease product (QIDP) OR\                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                          4) Submitted with a priority review voucher                                                                                                                                                                                                                                                                                                                                      

  Accelerated approval\                                      Submit during drug development\                                                                                                              1\) A drug for a serious condition, AND\                                                                                                                                                                                 Approval based on effect on a surrogate endpoint or an intermediate clinical endpoint that is reasonably likely to predict a drug\'s clinical benefit   Post‐marketing confirmatory trials to verify and describe the anticipated effect on IMM or other clinical benefit
  (FDA, 1992)                                                Response timing not specified                                                                                                                2) With a meaningful advantage over available therapies, AND\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                          3) Demonstrates an effect\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                          • on a surrogate endpoint that is reasonably likely to predict clinical benefit, OR\                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                          • on an intermediate clinical endpoint that is reasonably likely to predict clinical benefit                                                                                                                                                                                                                                                                                     

  Fast track\                                                Submit with IND or after;\                                                                                                                   1\) A drug for a serious condition AND nonclinical or clinical data with the potential to address unmet medical need OR\                                                                                                 Actions to expedite development and review;\                                                                                                            Not requested
  (FDA, 1998)                                                ideally, no later than the pre‐BLA or pre‐NDA meeting\                                                                                       2) A drug designated as a QIDP                                                                                                                                                                                           Rolling review                                                                                                                                          
                                                             Response within 60 calendar days of receipt of request                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Breakthrough therapy\                                      Submit with IND or after;\                                                                                                                   A drug for a serious condition AND preliminary clinical evidence with substantial improvement on a clinically significant endpoint(s) over available therapies                                                           Intensive guidance on efficient drug development;\                                                                                                      Not requested
  (FDA, 2012)                                                ideally no later than the end‐of‐phase‐2 meeting\                                                                                                                                                                                                                                                                                                                     Organizational commitment;\                                                                                                                             
                                                             Response within 60 calendar days of receipt of request                                                                                                                                                                                                                                                                                                                Rolling review                                                                                                                                          

  Expedited access pathway\                                  Submit prior to commencement of an IDE pivotal study\                                                                                        A device intended to treat or diagnose a life‐threatening or irreversibly debilitating disease or condition AND addresses an unmet need                                                                                  Reduces premarket data                                                                                                                                  Post‐approval data collection may be required for conditional approval (data collection should begin within 6 months of, and be submitted within 3 years of, approval data)
  (FDA, 2015)                                                Meeting will be held within 75‐90 days of request with pre‐submission by the sponsor                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **EU**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Accelerated assessment\                                    Submit request at least 2‐3 months before submission of marketing authorization application (MAA)\                                           Medicinal products of major interest to public health AND therapeutic innovation perspective (unmet medical need)                                                                                                        Reduced MAA assessment time to 150‐day maximum compared to standard 210 days                                                                            Not requested
  (EMA, 2004)                                                Conclusions on request for accelerated assessment communicated to applicant prior to start of product assessment.                                                                                                                                                                                                                                                                                                                                                                                                             

  Marketing authorization under exceptional circumstances\   Submit before MAA\                                                                                                                           1\) Indications encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, OR\                                                                                            Authorization without comprehensive data on efficacy and safety                                                                                         The applicant shall complete an identified programme of studies within the time period specified by the competent authority, the results of which shall form the basis of a reassessment of the benefit/risk profile\
  (EMA, 2005)                                                No response timeframe specified                                                                                                              2) In the present state of scientific knowledge, comprehensive information cannot be provided, OR\                                                                                                                                                                                                                                                                               (Does not normally lead to standard authorization)
                                                                                                                                                                                                          3) It would be contrary to generally accepted principles of medical ethics to collect such information                                                                                                                                                                                                                                                                           

  Conditional marketing authorization (EMA, 2006)            Request at submission of MAA. The CHMP also proposed a conditional marketing authorization during assessment of MAA\                         Medical products for:\                                                                                                                                                                                                   Earlier authorization of medicines for patients with unmet medical needs, based on less complete clinical data                                          Comprehensive data generated post‐authorization within agreed timeframe\
                                                             Assessed as part of the scientific review during assessment of MAA                                                                           • Seriously debilitating or life‐threatening diseases\                                                                                                                                                                                                                                                                                                                           (Valid for one year; thereafter, conditional marketing authorization may be renewed annually)
                                                                                                                                                                                                          • Emergency situations\                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                          • Orphan medicinal products,\                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                          AND\                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                          Fulfilling all of the following criteria:\                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                          • Positive risk‐benefit balance\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                          • Applicant likely to be able to provide comprehensive data after authorization\                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                          • Fulfillment of unmet medical need\                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                          • Benefits of immediate availability outweigh the risks that additional data are still required                                                                                                                                                                                                                                                                                  

  Adaptive pathway approach\                                 Contact EMA to discuss the draft content and determine suitability of their request to be considered for the pilot programme case‐by‐case\   Treatments in area of high medical need where it is difficult to collect data via traditional routes and where large clinical trials would unnecessarily expose patients who are unlikely to benefit from the medicine   Scientific advice by the authority;\                                                                                                                    Patient registries and other pharmacovigilance tools that allow collection of real‐life data and development of a risk‐management plan
  (EMA, 2015)                                                No response timeframe specified                                                                                                                                                                                                                                                                                                                                       Compassionate use;\                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                   The conditional approval mechanism                                                                                                                      

  Accelerated assessment of priority medicines, PRIME\       Submit during the drug development, based on preliminary clinical evidence (proof of concept);\                                              Fulfills unmet clinical need                                                                                                                                                                                             Identify potential for accelerated assessment earlier in development:\                                                                                  N/A
  (EMA, 2016)                                                Exceptionally earlier access to SMEs and academics (proof of principle); at least first in man                                                                                                                                                                                                                                                                        − Early rapporteur appointment\                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                   − Reinforced scientific and regulatory support from the SAWP/CHMP, other relevant scientific committees, and EMA\                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                   − Dedicated contact person within EMA                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BLA, Biologics License Application; CHMP, Committee for Human Medicinal Products; EMA, European Medicines Agency; EU, European Union; FDA; Food and Drug Administration; IMM, irreversible morbidity or mortality; IND, Investigational New Drug; IDE, Investigational Device Exemption; MAA: Marketing Authorization Application; NDA, New Drug Application; USA, United States of America.

###### 

Categorization of expedited or special pathways in the USA and EU

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Category**                                             **Expedited pathway or programme (Authority)**   **Requirement of efficacy/benefit‐risk balance clinical data**   **Review/ evaluation of post‐marketing data**   
  -------------------------------------------------------- ------------------------------------------------ ---------------------------------------------------------------- ----------------------------------------------- --------------
  1\. Expedited approval (with no conditions)              ‐ Priority review (FDA)\                         Comprehensive data are required                                  Not required                                    Not required
                                                           ‐ Fast track (FDA)\                                                                                                                                               
                                                           ‐ Accelerated assessment (EMA)                                                                                                                                    

  2\. Conditional approval                                 ‐ Accelerated approval (FDA)\                    Comprehensive data are not required\                             Required                                        Required
                                                           ‐ Expedited approval pathway (FDA)\              Early, surrogate, or intermediate endpoints are accepted                                                         
                                                           ‐ Conditional marketing authorization (EMA)                                                                                                                       

  3\. Approval with limited patient cohort or indication   ‐ MA under exceptional circumstances (EMA)       Not required                                                     Not required                                    Not required

  4\. Development support                                  ‐ Breakthrough therapy (FDA)\                    Comprehensive data are required                                  Not required (except for adaptive pathway)      Not required
                                                           ‐ Adaptive pathways (EMA)\                                                                                                                                        
                                                           ‐ PRIME (EMA)                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EMA, European Medicines Agency; EU, European Union; FDA; Food and Drug Administration; USA, United States of America.

If the new Japanese expedited‐approval pathway were to be categorized into one of the above groups, it would fit into group 2.

3.2. Qualifying criteria for expedited‐approval pathways and programmes in the USA and EU, and comparison with those of the conditional and time‐limited approval of regenerative medicine products in Japan {#term2428-sec-0007}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Based on the guidance documents for the various US and EU pathways and programmes, the following qualifying criteria for candidate medical products were found to be common between two or more pathways or programmes. The candidate medical product: Treats a serious or life‐threatening target disease;Treats a limited target disease patient population (e.g. orphan disease);Treats a disease lacking medical treatment options (e.g. unmet medical needs);Is superior to existing medical treatment options.

These conditions are summarized in Table [3](#term2428-tbl-0003){ref-type="table-wrap"} (✓, pathways/programmes that include these criteria; ‐, those without these criteria). Briefly, most pathways had a requirement that the candidate medical product should address unmet medical needs. Almost two thirds of the examined expedited‐approval pathways or programmes required that the products were intended for serious or life‐threatening diseases. All of the analysed pathways include one or more of these four criteria.

###### 

Summary of qualifying criteria for expedited pathways/programmes for medical products

  **Regulatory pathway (Authority)**                               **Serious/life‐threatening target disease**     **Limited/orphan patient population**     **No alternative treatment options**   **Superior to existing treatment**
  --------------------------------------------------------------- --------------------------------------------- ------------------------------------------- -------------------------------------- ------------------------------------
  Priority review (FDA)                                             ✓[a](#term2428-note-0004){ref-type="fn"}     --[b](#term2428-note-0005){ref-type="fn"}                    --                                    ✓
  Accelerated approval (FDA)                                                            ✓                                           --                                        --                                    ✓
  Fast track (FDA)                                                                      ✓                                           --                                        ✓                                     --
  Breakthrough therapy (FDA)                                                            ✓                                           --                                        --                                    ✓
  Expedited access pathway (FDA)                                                        ✓                                           --                                        ✓                                     --
  Accelerated assessment (EMA)                                                         --                                           --                                        ✓                                     --
  Marketing authorization under exceptional circumstances (EMA)                        --                                            ✓                                        --                                    --
  Conditional marketing authorization (EMA)                                             ✓                                            ✓                                        ✓                                     --
  Adoptive pathway (EMA)                                                               --                                            ✓                                        ✓                                     --
  PRIME (EMA)                                                                          --                                           --                                        ✓                                     --

: Required.

: Not required.

FDA, US Food and Drug Administration; EMA, European Medicines Agency

We analysed the applicable provisions of the conditional and time‐limited approval of the PMD Act. (Ministry of Welfare, Health and Labor, [2013](#term2428-bib-0013){ref-type="ref"}) Part 1, Articles 23‐26 of the Act is the only portion containing similar qualifying criteria, as outlined below: The regenerative medicine product is not homogeneous;The clinical data on the products are likely to predict efficacy;The product does not exhibit remarkably adverse results in efficacy, effectiveness or performance.

There is no definition of 'homogeneous' in the legislation; this designation for conditional and time‐limited approval is to be determined based on consultation with the Pharmaceutical Affairs and Food Sanitation Council (Part 1, Article 23‐26 of the Act).

3.3. Japanese standards for collecting post‐marketing clinical data under conditional and time‐limited approval {#term2428-sec-0008}
---------------------------------------------------------------------------------------------------------------

After obtaining conditional and time‐limited approval, the marketing authorization holder must submit a standard authorization application with data collected from all patients treated with the product over the allocated conditional approval period. The quality and compliance requirements fulfilled for post‐marketing study of conditional and time‐limited approved products is the Good Post‐marketing Study Practice (GPSP) (Ministry of Welfare, Health and Labor, [2014b](#term2428-bib-0015){ref-type="ref"}) which is usually applied for post‐marketing surveillance (PMS) (Part 5, Article 23‐26 of the Act). PMS is generally required for 'novel' medical products (no similar or predicated product approved in Japan). In contrast, the clinical data submitted to the regulatory authority for pursuing the standard approval must comply with Good Clinical Practice (GCP) (Part 3, Article 23‐25 of the Act) (Ministry of Welfare, Health and Labor, [2014a](#term2428-bib-0014){ref-type="ref"}).

3.4. Clinical data for conditional and time‐limited approval and post‐marketing clinical data requirements {#term2428-sec-0009}
----------------------------------------------------------------------------------------------------------

As of the of the end of September 2016, two regenerative medicine products have been approved under the new Japanese Act (Pharmaceuticals and Medical Devices Agency, 2016c, 2016d). One of them, HeartSheet® (Terumo), was granted conditional and time‐limited approval on 18 September 2015. The product is made of autologous skeletal myoblasts, and is used to treat patients with serious heart failure (Ministry of Health, Labor and Welfare, [2015a](#term2428-bib-0011){ref-type="ref"}). The applicant medical product demonstrated probable benefit in one multi‐centre, open‐label, single‐arm, feasibility study with seven patients (Ministry of Health, Labor and Welfare, [2015a](#term2428-bib-0011){ref-type="ref"}). To obtain standard approval, a standard authorization application with data collected from all cases treated with the product over the allocated conditional approval period, which was five years, must be submitted. Although the maximum time of conditional approval is regulated as seven years (Part 1, Article 23‐26 of the Act), the reasons for the five‐year approval were not described in the review report. Patients enrolled into the study were 60 for the product arm and 120 for the control arm, not treated with the product, but identified with similar clinical conditions.

The second product, TemCell HS Injection® (JCR Pharmaceuticals Co. Ltd.), was approved on September 18, 2015 (Ministry of Health, Labor and Welfare, [2015b](#term2428-bib-0012){ref-type="ref"}). Unlike HeartSheet, it was granted standard approval. It is an allogenic cell therapy product, and intended to treat an orphan disease, acute graft‐versus‐host disease (aGVHD) after an allogeneic bone marrow transplant. Unlike the case with HeartSheet, one condition for approval is collecting data on all cases treated with the product, which should be registered as PMS.

4. Discussion {#term2428-sec-0010}
=============

Through comparative analysis, the following three major differences between the new Japanese system and the existing US and EU systems were identified, and we focus on these in our discussion. The new Japanese expedited‐approval system does not specify the severity of the target disease, or patient population, or make comparisons with existing treatment conditions or requirements for conditional and time‐limited approval, as in the expedited‐approval pathways and programmes in the USA and EU.The Japanese system contains a time‐limited (maximum seven years) and conditional approval, while the USA and EU have no time limitations on any marketing of specialized drug approvals.The standard required for post‐marketing study in Japan is a unique practice, and is specialized for data collection in the post‐marketing setting.

4.1. Qualifying criteria for the expedited‐approval pathways and programmes {#term2428-sec-0011}
---------------------------------------------------------------------------

We have clarified that the Act in Japan does not specify the qualifying criteria for conditional and time‐limited approval, as is the case for the expedited‐approval pathways and programmes in the USA and EU. Furthermore, under the new Act, designation of the programme is determined during the review process by consulting an external review board, meaning that decisions are made at a late stage in the review process as compared to the US and EU systems (Ministry of Welfare, Health and Labor, [2013](#term2428-bib-0013){ref-type="ref"}). However, since only two products have been approved through the new Japanese system, comparisons between these products can be made based on the collective characteristics of their procedures and characteristics. According to our analysis of the HeartSheet review report the target disease was severe chronic heart failure, a serious and life‐threatening condition, and there was no realistic alternative medical treatment. However, these conditions were not detailed in the legislation. Without clarifying whether the data from phase II studies (or pilot studies) are likely to be accepted under the expedited approval as specified in the Act, it is challenging for applicants or sponsors to formulate a development plan in advance without clear guidance. In addition to institutionalization of the qualifying criteria, considering the fact that recent applications have not always met qualifying criteria in the USA (Kesselheim*, et al.*, [2015](#term2428-bib-0009){ref-type="ref"}), mechanisms for preventing the applications that fall outside specified programme conditions should be established.

4.2. Advantage of time‐limitation of marketing authorization {#term2428-sec-0012}
------------------------------------------------------------

In the USA, sponsors do not sufficiently uphold and complete their obligation to collect post‐marketing data (Moore and Furberg, [2014](#term2428-bib-0016){ref-type="ref"}). Concerning expedited‐approval programmes in the EU, it has been reported that there were delays or discrepancies in the fulfilment of the post‐market obligations in more than one third of the conditional approvals (Banzi *et al.*, [2015](#term2428-bib-0001){ref-type="ref"}). Moreover, as in the example of Midodrine in the USA (Dhruva and Redberg, [2010](#term2428-bib-0004){ref-type="ref"}), it has sometimes become difficult for authorities to withdraw products of questionable efficacy from the market because of appeals made by professional organizations, health care professionals and patients.

Compared with these concerning complications in the US and EU programmes, the time‐limitation of marketing approval for regenerative medicine products in Japan is unique, enabling conditional approval to be automatically withdrawn if the applicant or sponsor cannot obtain standard approval during the allocated period. This additional requirement is intended to improve sponsor compliance with post‐marketing obligations.

4.3. Standard or practice requirements for post‐marketing study of conditional and time‐limited approval {#term2428-sec-0013}
--------------------------------------------------------------------------------------------------------

As described in the Results section, GPSP is the required standard for conducting PMS for conditional and time‐limited approval products. GPSP is a unique Japanese standard applied to PMS and required for unique medical products without precedent approvals. For example, monitoring and self‐auditing are imperative under GCP, but are not required under GPSP. However, under the new Japanese legislation the authority conducts a conformity audit after data submission for regulatory purposes. Therefore, GPSP applies a less rigid standard in terms of data reliability. Practically, it would become more challenging to conduct clinical trials (studies) to determine efficacy before approval because of the difficulty of enrolling a sufficient number of patients (Darrow *et al.*, [2014](#term2428-bib-0003){ref-type="ref"}). Since PMS confirmatory clinical data are required to be submitted by the end of the limited permitted marketing period, it seems counter‐intuitive to apply criteria less rigourous than those for the standard approval conducted under GCP. As HeartSheet treats serious heart failure, it would be challenging for the sponsor to design studies to obtain confirmatory efficacy data from post‐marketing studies where finding control or placebo groups could be difficult. Given that a product\'s effectiveness should be proven by a post‐marketing study or by surveillance, additional mechanisms for using such non‐GCP study data to confirm safety and efficacy should be implemented.

Both the time limitation for expedited approval and the standards set for post‐marketing surveillance are unique systems in Japan that would be another solution for more effectively enforcing compliance with post‐marketing obligations. There are many variations in expedited‐approval pathways and programmes in the USA, the EU and Japan; however, efforts to improve the respective systems should focus on solving the problems unique to each existing framework.

5. Conclusions {#term2428-sec-0014}
==============

The expedited‐approval pathways and programmes in the USA, the EU and Japan play a key regulatory role in accelerating the development of medical products, including regenerative medicine products for unmet medical needs. Improvements in the expedited‐approval pathways and programmes are necessary to solve the problems inherent in the existing systems. Our study shows that the characteristics of the new Japanese legislation may improve institutionalization of the other expedited‐approval pathways and programmes.
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